IL150978A0 - Nitroacridine/tumor inhibitor compositions - Google Patents

Nitroacridine/tumor inhibitor compositions

Info

Publication number
IL150978A0
IL150978A0 IL15097801A IL15097801A IL150978A0 IL 150978 A0 IL150978 A0 IL 150978A0 IL 15097801 A IL15097801 A IL 15097801A IL 15097801 A IL15097801 A IL 15097801A IL 150978 A0 IL150978 A0 IL 150978A0
Authority
IL
Israel
Prior art keywords
nitroacridine
tumor inhibitor
inhibitor compositions
compositions
tumor
Prior art date
Application number
IL15097801A
Other languages
English (en)
Original Assignee
New York Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College filed Critical New York Medical College
Publication of IL150978A0 publication Critical patent/IL150978A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15097801A 2000-02-18 2001-02-16 Nitroacridine/tumor inhibitor compositions IL150978A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18352900P 2000-02-18 2000-02-18
PCT/US2001/005276 WO2001060351A2 (fr) 2000-02-18 2001-02-16 Compositions inhibitrices de tumeurs a base de 1-nitroacridine

Publications (1)

Publication Number Publication Date
IL150978A0 true IL150978A0 (en) 2003-02-12

Family

ID=22673188

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15097801A IL150978A0 (en) 2000-02-18 2001-02-16 Nitroacridine/tumor inhibitor compositions
IL150978A IL150978A (en) 2000-02-18 2002-07-30 Nitroacridine/tumor inhibitor compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150978A IL150978A (en) 2000-02-18 2002-07-30 Nitroacridine/tumor inhibitor compositions

Country Status (13)

Country Link
US (1) US7622478B2 (fr)
EP (1) EP1261325B1 (fr)
AT (1) ATE480237T1 (fr)
AU (1) AU2001238499A1 (fr)
CA (1) CA2400403C (fr)
CY (1) CY1111289T1 (fr)
DE (1) DE60143023D1 (fr)
DK (1) DK1261325T3 (fr)
ES (1) ES2352175T3 (fr)
IL (2) IL150978A0 (fr)
MX (1) MXPA02008014A (fr)
PT (1) PT1261325E (fr)
WO (1) WO2001060351A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US8647627B2 (en) 2011-01-13 2014-02-11 Oncbiomune, L.L.C. Composition for a cancer vaccine
US20230286919A1 (en) * 2020-04-01 2023-09-14 Vestlandets Innovasjonsselskap As Isoquinoline derivatives for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694447A (en) 1970-03-10 1972-09-26 Smith Kline French Lab Complexes of phosphanilic acid and 9-amino-3-nitroacridine
PL106752B1 (pl) 1976-02-25 1980-01-31 Politechnika Gdanska Sposob otrzymywania nowych 1-nitro-9-alkiloaminoalkiloaminoakrydyn lub ich soli
PL126407B1 (en) 1980-04-23 1983-07-30 Politechnika Gdanska Process for preparing 1-nitro-9-hydroxyalkylaminoacridines or their salts
NZ200715A (en) 1982-05-24 1986-06-11 New Zealand Dev Finance Acridine derivatives and pharmaceutical compositions containing such
US4985436A (en) 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
KR100220538B1 (ko) 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
JPH05331070A (ja) * 1992-02-07 1993-12-14 Takeda Chem Ind Ltd Ｔｎｐとインターロイキンとを含有してなる抗腫瘍剤
US5696131A (en) 1993-01-22 1997-12-09 Xenova Limited Treatment of cancers
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CA2189051C (fr) 1994-04-29 2008-06-17 M. Jules Mattes Composition destinee a l'apport de radio-isotopes toxiques au noyau de la cellule, et son utilisation
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5529989A (en) 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
KR0160110B1 (ko) 1995-05-24 1998-12-01 한영복 항암제 조성물
CA2303401A1 (fr) * 1997-10-01 1999-04-08 G.D. Searle & Co. Proteines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement anti-tumeur
WO1999034788A1 (fr) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthese de phenstatine et promedicaments de celle-ci
AU3980499A (en) * 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
WO2000048606A1 (fr) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions et procedes servant au ciblage de la destruction vasculaire

Also Published As

Publication number Publication date
DK1261325T3 (da) 2010-12-20
ATE480237T1 (de) 2010-09-15
US7622478B2 (en) 2009-11-24
WO2001060351A2 (fr) 2001-08-23
DE60143023D1 (de) 2010-10-21
CA2400403A1 (fr) 2001-08-23
EP1261325A2 (fr) 2002-12-04
US20020037831A1 (en) 2002-03-28
MXPA02008014A (es) 2004-04-05
PT1261325E (pt) 2010-12-10
CA2400403C (fr) 2011-07-19
EP1261325B1 (fr) 2010-09-08
WO2001060351A3 (fr) 2002-01-24
ES2352175T3 (es) 2011-02-16
IL150978A (en) 2010-06-30
CY1111289T1 (el) 2015-08-05
AU2001238499A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
WO2002022576A3 (fr) Indoles substitues en 3 inhibiteurs de l'angiogenese et de la proliferation cellulaire
AU3652102A (en) Compounds and their uses
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU8112101A (en) Non-imidazole aryloxypiperidines
WO2000004954A3 (fr) Nouveaux inhibiteurs d'urokinase
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
WO2003039545A3 (fr) Utilisation d'inhibiteurs de i$g(k)b kinase pour traiter le cancer
WO2003084475A3 (fr) Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs
GB2378948B (en) Novel compounds for modulating cell proliferation
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
MXPA03004879A (es) Inhibidores de farnesiltransferasa.
MXPA04005942A (es) Composiciones y metodos de sintaxina 3.
WO2002020000A3 (fr) Blocage d'oestrogene du sein combine au moyen d'exemestane et de raloxifene
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
WO2002032429A3 (fr) Inhibition de la dependance des cellules tumorales par rapport au facteur de croissance
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
WO2005032595A3 (fr) Procedes et compositions d'inhibition de stat5 dans des cellules cancereuses de la prostate
WO2001028593A3 (fr) Processus de preparation de conjugues convenant pour le traitement du cancer de la prostate
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
WO2002028432A3 (fr) Procedes reposant sur l'utilisation de cellules embryonnaires pour la prevention et le traitement de la tumorigenese
PT1276722E (pt) Inibidores de naftamidina-uroquinase
AU2003264707A1 (en) Use of a chrysanthellum extract
WO2005048956A3 (fr) Composes se rapportant a l'oestradiol, et procedes d'utilisation comme agents antitumoraux